Published in Radiat Oncol on April 08, 2011
Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol (2014) 1.21
Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys (2014) 1.18
Radical irradiation of extracranial oligometastases. J Clin Oncol (2014) 1.07
Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. Can Urol Assoc J (2015) 1.03
Surgical intervention for pulmonary metastases. Dtsch Arztebl Int (2012) 1.02
Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease. Br J Radiol (2015) 0.91
A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer. Pulm Med (2012) 0.90
Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol (2014) 0.90
Role of radiation therapy in the management of renal cell cancer. Cancers (Basel) (2011) 0.89
Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant? Pract Radiat Oncol (2015) 0.87
Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases. Pract Radiat Oncol (2013) 0.87
Stereotactic body radiotherapy treatment of extracranial metastases. Nat Rev Clin Oncol (2012) 0.84
Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. Cancer Immunol Immunother (2014) 0.83
Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases. J Thorac Dis (2015) 0.81
Radiation therapy for cutaneous melanoma. Dermatol Clin (2012) 0.81
Clinical applicability of biologically effective dose calculation for spinal cord in fractionated spine stereotactic body radiation therapy. Radiol Oncol (2015) 0.80
SBRT for lung oligometastases: Who is the perfect candidate? Rep Pract Oncol Radiother (2014) 0.80
Novel application of stereotactic ablative radiotherapy using CyberKnife(®) for early-stage renal cell carcinoma in patients with pre-existing chronic kidney disease: Initial clinical experiences. Oncol Lett (2014) 0.80
Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013. Can Urol Assoc J (2013) 0.79
Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther (2013) 0.79
Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiat Oncol (2015) 0.79
Efficacy and safety of image-guided interstitial single fraction high-dose-rate brachytherapy in the management of metastatic malignant melanoma. J Contemp Brachytherapy (2015) 0.78
Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy. Int J Radiat Oncol Biol Phys (2015) 0.78
International patterns of practice in radiotherapy for bone metastases: A review of the literature. J Bone Oncol (2014) 0.78
To combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma. World J Urol (2013) 0.77
Radiofrequency ablation alone or in combination with cementoplasty for local control and pain palliation of sacral metastases: preliminary results in 11 patients. Skeletal Radiol (2016) 0.76
Integrating metastasectomy and stereotactic radiosurgery in the treatment of metastatic renal cell carcinoma. EJC Suppl (2013) 0.76
Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes. J Clin Oncol (2014) 0.76
Retrospective analysis of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) in comparison with a contemporaneous cohort of primary lung lesions (PLLs). J Thorac Dis (2017) 0.75
Radiation therapy following targeted therapy in oligometastatic renal cell carcinoma. Mol Clin Oncol (2015) 0.75
Establishment of linear accelerator-based image guided radiotherapy for orthotopic 4T1 mouse mammary tumor model. Lab Anim Res (2014) 0.75
Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. Int J Radiat Oncol Biol Phys (2017) 0.75
Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (2003) 7.86
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol (2004) 5.38
Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys (2008) 5.03
Oligometastases. J Clin Oncol (1995) 4.95
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol (2009) 4.59
Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol (2009) 3.00
A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys (2005) 2.41
Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol (2001) 2.28
A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys (2004) 1.75
Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys (2006) 1.66
Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol (2005) 1.45
FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer (2007) 1.41
A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys (1996) 1.35
A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys (2009) 1.29
Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann Thorac Surg (2007) 1.20
Radiation therapy of malignant melanoma: experience with high individual treatment doses. Cancer (1976) 1.16
Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys (1991) 1.15
Outcome variation among "radioresistant" brain metastases treated with stereotactic radiosurgery. Neurosurgery (2005) 1.14
Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys (2009) 1.13
Stereotactic radiosurgery for patients with "radioresistant" brain metastases. Neurosurgery (2002) 1.12
Liver resection for metastases from renal cell carcinoma. World J Surg (2007) 1.09
Stereotactic radiosurgery with or without whole brain radiotherapy for patients with a single radioresistant brain metastasis. Am J Clin Oncol (2010) 1.06
Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma. J Neurosurg (2008) 1.03
Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol (2006) 1.03
Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma. Neurosurgery (2009) 0.97
Strategies for treating possible tumor extension: some theoretical considerations. Int J Radiat Oncol Biol Phys (1985) 0.95
The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer (1983) 0.93
Stereotactic radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases. World Neurosurg (2009) 0.92
Radiation therapy in the treatment of metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys (1985) 0.92
Proceedings: Cancer of the kidney--radiation therapy and its indications in non-Wilms' tumors. Cancer (1973) 0.89
A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys (1985) 0.88
Stereotactic body radiotherapy in the management of painful bone metastases. Oncology (Williston Park) (2008) 0.87
Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer (1992) 0.85
Treatment of oligometastases after successful immunotherapy. Semin Radiat Oncol (2006) 0.85
The radiosensitivity of melanoma cells in culture. Br J Radiol (1971) 0.84
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Head and neck cancer. Lancet (2008) 6.33
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med (2011) 4.68
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol (2009) 4.59
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 3.80
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol (2009) 3.00
Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol (2007) 2.80
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther (2007) 2.71
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol (2012) 2.47
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys (2005) 2.41
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Radiation-associated liver injury. Int J Radiat Oncol Biol Phys (2010) 2.39
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 2.26
Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys (2009) 2.14
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer (2011) 1.87
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res (2006) 1.82
Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys (2010) 1.74
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res (2006) 1.72
A model for harmonizing flow cytometry in clinical trials. Nat Immunol (2010) 1.70
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells (2012) 1.70
Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol (2007) 1.69
Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head Neck (2006) 1.65
Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol (2010) 1.55
Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol (2006) 1.53
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51
Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg (2013) 1.50
The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol (2007) 1.49
Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys (2008) 1.47
A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs (2009) 1.47
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res (2002) 1.43
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol (2005) 1.37
Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A (2013) 1.35
Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res (2006) 1.31
Metastatic melanoma in the breast: a report of 27 cases. J Surg Oncol (2006) 1.31
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol (2013) 1.28
Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res (2011) 1.27
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer (2010) 1.24
Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol (2011) 1.22
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res (2010) 1.19
Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer (2008) 1.16
Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys (2009) 1.13
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol (2012) 1.12
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function. J Cancer Sci Ther (2009) 1.11
Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report. BMC Cancer (2007) 1.11
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs (2007) 1.09
Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study. Int J Radiat Oncol Biol Phys (2008) 1.09
Survival in sentinel lymph node-positive pediatric melanoma. J Pediatr Surg (2005) 1.08
Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol (2009) 1.07
Resource loss, coping, alcohol use, and posttraumatic stress symptoms among survivors of Hurricane Katrina: a cross-sectional study. Am J Disaster Med (2009) 1.07
Toward a unified survival curve: in regard to Park et al. (IntJ Radiat Oncol Biol Phys 2008;70:847-852) and Krueger et al. (Int J Radiat Oncol Biol Phys 2007;69:1262-1271). Int J Radiat Oncol Biol Phys (2008) 1.07
Melanoma, version 4.2014. J Natl Compr Canc Netw (2014) 1.07
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer (2010) 1.06
Partial breast brachytherapy after lumpectomy: low-dose-rate and high-dose-rate experience. Int J Radiat Oncol Biol Phys (2003) 1.05
Stereotactic body radiation therapy. Rationale, techniques, applications, and optimization. Oncology (Williston Park) (2004) 1.05
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res (2005) 1.04
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol (2006) 1.03
Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2010) 1.02
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.02
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol (2009) 1.01
Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer. Semin Radiat Oncol (2002) 0.99
PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs (2008) 0.99
Anti-citrullinated peptide autoantibodies, human leukocyte antigen shared epitope and risk of future rheumatoid arthritis: a nested case-control study. Arthritis Res Ther (2013) 0.99
Survival and patterns of relapse in patients with oral tongue cancer. J Oral Maxillofac Surg (2009) 0.98
Desmoid tumors of the right rectus abdominus muscle in postpartum women. Arch Gynecol Obstet (2008) 0.98
Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg (2005) 0.98
Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg (2005) 0.97
Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol (2009) 0.97
Perioperative Mortality in Nonelderly Adult Patients With Cancer: A Population-based Study Evaluating Health Care Disparities in the United States According to Insurance Status. Am J Clin Oncol (2016) 0.97
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res (2006) 0.96
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2012) 0.96
A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer (2002) 0.94
A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res (2010) 0.94